Stable compositions of highly soluble FOXY-5 hexapeptides

By forming stable and soluble mono-, di-, and trisalts of Foxy-5 with nitrogenous bases, the solubility and stability issues of Foxy-5 are addressed, enabling its effective use in clinical trials and commercial production.

JP2024545142AInactive Publication Date: 2024-12-05WNTRES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024534336
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-10
Filing Date
2022-12-08
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The limited solubility of Foxy-5 in water hinders its commercial production, and the trisodium salt, while having high solubility, is unstable, making it unsuitable for clinical trials and commercial use.

Method used

Development of mono-, di-, and trisalts of Foxy-5 with various nitrogenous bases such as ammonia, quaternary ammonium hydroxide, alkylated guanidine, and amino acids, which are more stable and soluble, allowing for increased solubility up to 150 mg/ml.

Benefits of technology

The new salt forms of Foxy-5 provide enhanced stability and solubility, overcoming the limitations of the trisodium salt, facilitating its use in clinical trials and commercial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545142000001_ABST
    Figure 2024545142000001_ABST
Patent Text Reader

Abstract

The present disclosure relates to novel, highly soluble compositions of the Wnt hexapeptide Foxy-5. Additionally, the present disclosure relates to methods for producing and evaluating the stability of the compositions.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to novel, highly soluble compositions of the Wnt hexapeptide Foxy-5. Additionally, the present disclosure relates to methods for making said compositions and evaluating their stability. [Background technology]

[0002] Foxy-5 is a formylated WNT5A-derived hexapeptide and WNT5A mimetic with potential antimetastatic activity currently being developed as a drug candidate for preventing tumor spread and recurrence in multiple common cancers. Foxy-5 has the formula For-Met-Asp-Gly-Cys-Glu-Leu-OH (Sequence 1, Figure 1).

[0003] When administered intravenously, Foxy-5 binds to and activates the WNT5A receptor, which activates WNT5A-mediated signaling, primarily of the Frizzled family.

[0004] Foxy-5 is intended to compensate for the loss of the protein WNT5A in tumor tissues of cancer patients where WNT5A ligands act as tumor suppressors to reduce the risk of metastasis. A subanalysis of a recent retrospective study of stage III colon cancer patients has shown that the proportion of patients with low expression of WNT5A was significantly higher than that observed in a previous study of stage II colon cancer (CRC) patients. Patients with CRC stage III tumors differ from stage II primarily in the presence of tumor cells in lymph nodes near the primary tumor, which makes them more aggressive and progress faster. Low levels of WNT5A were observed in nearly 70 percent of stage III patients compared to approximately 45 percent of patients with less advanced tumor stages. Similar findings were seen in breast cancer tissues, where an absence or low level of WNT5A was observed in 70% of aggressive triple-negative breast cancers compared to approximately 45% of less aggressive breast cancer types. It has been demonstrated that the absence or low levels of WNT5A in the primary tumor is associated with faster recurrence in several types of cancer, including breast, colon, prostate, and hepatocellular carcinoma, when compared with tumors with normal or near-normal expression of the WNT5A protein, supporting the hypothesis that WNT5A levels have a profound effect on the course of the disease.

[0005] Based on a completed Phase 1b study with Foxy-5 aimed at documenting the safety profile, pharmacokinetics and dose determination of the drug candidate for Phase 2, Foxy-5 is currently undergoing a Phase 2 clinical trial study, the NeoFox study, which includes stage II / III colon cancer patients who, at the time of diagnosis, were considered to have a high risk of recurrence after the primary tumor was surgically resected. An assessment of the risk of recurrence will be performed according to established evaluation criteria. The aim of the study is to demonstrate that Foxy-5 reduces the risk of recurrence, mainly in patients with low expression of WNT5A. The study is currently ongoing in 28 hospitals in Spain (16) and Hungary (12).

[0006] Foxy-5 itself and classical solid phase (SPSS) methods for its production are described in International Pat. Publication No. WO 2006 / 130082 (A PEPTIDE LIGAND TO IMPAIR CANCER CELL MIGRATION). Active pharmaceutical ingredients (APIs) for preclinical and early clinical studies have been produced by this route. Solution phase routes for Foxy-5 developed by the applicant are disclosed in International Patent Publication Nos. WO 2020 / 038878 (Solution phase routes for Wnt hexapeptides) and WO 2020 / 120198 (Linear solution phase synthesis for Wnt hexapeptides).

[0007] The current manufacturing process for Foxy-5 has limited aqueous solubility of the non-salt drug substance (DS), resulting in a lyophilized final product concentration of 3 g / L, which represents a severe yield-limiting obstacle for commercial manufacturing of Foxy-5.

[0008] Early attempts to overcome this problem led to the development of an alternative freeze-drying process using 30% aqueous acetonitrile as the solvent (replacing water). The developed process was applied to DS concentrations up to 7 g / L, i.e., a productivity improvement of >100%, was demonstrated in small-scale experiments and validated on a 35 g scale. Although this achievement is impressive, it still remains problematic to produce Foxy-5 on a commercial scale when the final step requires such high dilution.

[0009] As a result, increasing the batch size by other solubilization techniques rather than adjusting the solvent polarity was suggested. From studies of drug product (DP) dosage forms, it was known that changing Foxy-5 from a salt-free form to the sodium salt increased the DS solubility to a level of at least 20 g / L.

[0010] In this regard, Foxy-5 is known to contain three carboxylic acid moieties and no free amino groups, due to the formylation of the terminal amino group (Figure 1). Therefore, it is only possible to prepare salts of Foxy-5 with basic / alkaline compounds. Some fine chemical suppliers are known to offer compounds marketed as "trifluoroacetate salt of Foxy-5", which is actually just a lyophilisate containing free trifluoroacetic acid.

[0011] The conversion of Foxy-5 to its sodium salt has been investigated by the applicant. Foxy-5 has three carboxylic acid groups (Asp 2 , Glu 5 Since Foxy-5 contains 1, 2, and 3 equivalents of sodium hydroxide, the mono-, di-, and trisodium salts were generated by treating an aqueous slurry of Foxy-5 (25 g / L) with 1, 2, and 3 equivalents of sodium hydroxide. Aspartimide (<0.1%) and dimer A batch of the free acid of Foxy-5 containing (<0.1%) was used (see FIG. 2 for structure).

[0012] The monosodium salt of Foxy-5 was not completely soluble and gel formation was observed immediately after addition of NaOH (1 equiv., pH=3.84).

[0013] The disodium salt could be completely dissolved within 10 min of adding NaOH (2 equiv., pH=4.57). HPLC analysis of the solution showed an increased content of aspartimide impurity, while dimer formation was only detected at negligible levels. After lyophilization, 0.07% dimer and 0.79% aspartimide were detected.

[0014] The trisodium salt dissolved within 5 min after addition of NaOH (3 equiv., pH = 6.76) and showed a minimal increase in the aspartimide impurity, but an increase in dimer formation was observed: after lyophilization, 0.41% dimer and 0.17% aspartimide were detected.

[0015] Among the three salts, the trisodium salt was found to have the highest solubility of >100 g / L and thus initially seemed to be a promising new drug candidate.

[0016] However, in the stability test at 40 °C, the trisodium salt of Foxy-5 was found by mass spectrometry to immediately develop a significant amount of the impurities studied so far (Figure 3) and reach levels of 15 - 20% after 4 weeks at 40 °C.

[0017] Further studies of aqueous solutions of Foxy-5 at different pH values revealed that at pH 9, the content of aspartimide decreased significantly immediately after complete dissolution. After stirring the Foxy-5 solution at pH 9 for 2 hours (see Figure 4), the peak of aspartimide in the HPLC chromatogram completely disappeared (<LOD). Ring-opening of aspartimide is known to occur at high pH, causing the formation of either the parent compound or β-Asp and D-Asp derivatives. However, significant dimer formation was observed (2.5% after 2 hours at pH = 9). Identification of the dimer in the chromatogram was confirmed by co-elution with separately synthesized reference substances. In addition to the two known impurities (aspartimide and dimer), surprisingly, a third impurity of the trisodium salt was identified as the desulfurized Cys→Ala analog of Foxy-5 (see Figures 2 and 3), albeit in small amounts.

[0018] In summary, conversion of Foxy-5 to the trisodium salt can increase its solubility in water, but this compound is too unstable to qualify as a drug substance. Thus, different DS forms of Foxy-5 with satisfactory solubility and stability for further clinical trials and future commercial purposes are still sought.

[0019] Definitions As used herein, the term "nitrogen base" means a basic compound containing at least one nitrogen atom.

[0020] As used herein, the term "mono salt" or "mono-salt" refers to a composition containing 1 equivalent of Foxy-5 and 0.5 to 1.45 equivalents of a nitrogenous base, as defined herein.

[0021] As used herein, the term "di-salt" or "di-salt" refers to a composition containing 1 equivalent of Foxy-5 and 1.50 to 2.49 equivalents of a nitrogenous base, as defined herein.

[0022] As used herein, the term "tri-salt" or "tri-salt" refers to a composition containing 1 equivalent of Foxy-5 and 2.5 to 3.1 equivalents of a nitrogenous base, as defined herein.

[0023] As used herein, the term HT-XRPD means high-throughput X-ray powder diffraction.

[0024] As used herein, the term HPLC-CAD refers to HPLC equipped with a charged aerosol detector.

[0025] As used herein, the term UPLC-MS refers to ultra performance liquid chromatography with mass spectrometry detection.

[0026] As used herein, the term "thermal cycling" refers to a process in which the solid composition of the present invention is suspended in a solvent or solvent mixture and the resulting suspension is heated with stirring at 10°C±2°C / hour until a temperature of 50°C±2°C is reached in each cycle, after which the suspension is heated at 10°C±2°C / hour until a temperature of 5°C±2°C is reached. a. 20°C ± 2°C / hour for the first cycle; b. 10°C ± 2°C / hr for the second cycle, and c. 5°C ± 2°C / hr for the third cycle This refers to a process in which 1 to 3 cycles of cooling at 5°C are performed. Finally, the suspension is aged by stirring at 5°C ± 2°C for 1 to 3 days. The temperature profile is illustrated in Figure 11. Summary of the Invention

[0027] Foxy-5, as already mentioned, has three carboxylic acid groups: Asp2 , Glu 5 Foxy-5 is a formylated hexapeptide of the formula For-Met-Asp-Gly-Cys-Glu-Leu-OH containing a C-terminal carboxylic acid group and is therefore capable of forming mono-, di- and tri-salts with basic compounds. Foxy-5 is available in various combinations in the appropriate ratios of 1:1, 1:2 and 1:3 (Foxy-5:base). Nitrogen bases (defined herein as a basic compound containing at least one nitrogen atom). These compositions are hereinafter referred to as "salts" for convenience, even though not all compositions isolated as amorphous lyophilizates can be adequately (stoichiometrically) characterized as salts. Mono-, di- and tri-salts of Foxy-5 He said.

[0028] Surprisingly, the stability of these compositions, when measured at 40° C., was found to vary significantly, as discussed below. An overview of all compositions of the present invention and their impurity profiles is shown in FIG.

[0029] In a first aspect, the present invention provides a solid composition comprising For-Met-Asp-Gly-Cys-Glu-Leu-OH (sequence 1, Foxy-5) and a nitrogenous base selected from ammonia, a quaternary ammonium hydroxide, an alkylated guanidine, an amino acid and a primary and secondary amine.

[0030] In a second aspect, the present invention provides a method for producing a composition according to the first aspect, comprising the steps of: a) i. as a suspension in a solvent, or ii. As a powder The free acid form of For-Met-Asp-Gly-Cys-Glu-Leu-OH (sequence 1, Foxy-5) iii. mixing with 0.5 to 1.49 equivalents of a nitrogen base to produce a mono-salt of Foxy-5; iv. mixing with 1.50 to 2.49 equivalents of a nitrogenous base to produce a di-salt of Foxy-5; or v. mixing with 2.5 to 3.1 equivalents of a nitrogen base to produce a trisalt of Foxy-5; b) stirring the reaction mixture until a clear solution is obtained; and c) isolating the solid composition by precipitating, or freeze-drying or spray-drying the solution; The present invention provides a method for producing a composition, wherein the nitrogen base is a compound selected from ammonia, quaternary ammonium hydroxide, alkylated guanidine, amino acid, and primary and secondary amines, and all of steps a to c are carried out under an inert atmosphere as necessary.

[0031] In a third aspect of the present invention, the solid composition obtained in step c) of the second aspect is further subjected to i. Providing a suspension of the freeze-dried or spray-dried product in a solvent or solvent mixture; ii. subjecting the suspension to a thermal cycling step comprising 1-3 cycles of 5°C±2°C to 50°C±2°C, followed by aging the suspension at 5°C±2°C for 1-3 days; iii. isolating the product after thermal cycling, for example by filtration or centrifugation; subjecting the mixture to a thermal cycling process including In the thermal cycling step, the suspension is heated at 10°C ± 2°C / hr until it reaches 50°C ± 2°C, and then the suspension is cooled at 5°C ± 2°C / hr until it reaches 5°C ± 2°C. a. 20°C ± 2°C / hour for the first cycle; b. 10°C ± 2°C / hr for the second cycle, and c. 5°C ± 2°C / hr for the third cycle Finally, the suspension is aged by stirring at 5° C.±2° C. for 1-3 days before isolation, e.g., by filtration or centrifugation.

[0032] The temperature profile of the thermal cycling process is illustrated in FIG. [Brief description of the drawings]

[0033] [Figure 1]The diagram shows the chemical structure of Foxy-5 (Sequence 1). Foxy-5 is a linear peptide of six amino acids with a formylated N-terminus. All optically active amino acid residues are in the L-configuration. The molecular formula of Foxy-5 is C26H42N6O12S2 and the molecular weight is 694.8 g / mol (average mass). [Diagram 2] The diagram shows the chemical structures of the three main impurities of Foxy-5: A) Aspartimide derivative of Foxy-5 B) Cys-Cys dimer derivative of Foxy-5 C) Cys→Ala-analogue of Foxy-5 [Diagram 3] The figure shows the purity (HPLC area %) of three known impurities of the trisodium salt: "Aspartimide", "Dimer" and "Ala-analogue" at 0, 2 and 4 weeks of storage at 40° C. See detailed description for details. [Figure 4] The figure shows the follow-up of high pH treatment of Foxy-5 by HPLC: starting material (bottom), after dissolution (middle) and after 2 hours at pH 9 (top). The HPLC results are shown shifted in the y-direction for comparison purposes. [Diagram 5] The figures show the purity (HPLC area %) of the tri-salt (top panel) and di-salt (bottom panel) of the present invention at 0, 2 and 4 weeks of storage at 40° C. As can be seen, there is a greater variation in stability at 4 weeks for the tri-salt than for the di-salt. [Figure 6] The top figure compares the purity (HPLC area %) of tri-salts made with amino acids (Lys, Arg and His) versus other salt formers (choline, diethylamine, ammonia, N-Me-glucamine and tromethamine) at 0, 2 and 4 weeks storage at 40° C. The bottom figure shows a similar comparison for the di-salts. As can be seen from the figures, there is a general trend for salts made with amino acids to have greater stability than salts made with other salt formers. [Figure 7] The figure shows the purity (HPLC area %) at 0, 2 and 4 weeks of storage at 40° C. of selected salts of the invention having a purity by HPLC (area %) of at least 90% after 4 weeks of storage at 40° C. [Figure 8]The figure shows the purity (HPLC area %) of the freshly lyophilized tri-ammonium (NH), tri-tromethamine (TRO) and tri-N-methyl-glucamine (NMG) salts of Foxy-5 prepared by either 1) slowly adding base to an aqueous suspension of Foxy-5 while maintaining the pH below 6 during the addition, or 2) adding the entire amount of base all at once. As can be seen, the purity of the tri-ammonium salt is very strongly affected by the method of addition, while the purity of the tri-TRO and tri-NMG salts is relatively unaffected. [Figure 9] The figure shows powder X-ray diffraction (PXRD) results for lyophilized trivalent salts of Foxy-5: (from bottom to top): ammonia trisalt, N-methyl-D-glucamine trisalt, tromethamine trisalt, and histidine trisalt. The diffraction results are shifted in the y direction for comparison purposes. [Figure 10] The figure is a table summarizing all performed experiments resulting in isolated solid compositions of the invention divided into "di-salt" and "tri-salt". The change in impurity profile over time (0, 2 and 4 weeks storage at 40° C.) for each composition and starting material (free acid of Foxy-5) is shown. [Figure 11] The figure shows the temperature profile used for "thermal cycling" of Foxy-5 compositions HIS-GEN14, HIS-GEN15 (L-histidine 1:2 and 1:3) and NMG-GEN16 (N-methyl-D-glucamine (1:2)). Samples were suspended in organic solvent and stirred at 5±2°C to 50°C±2°C. The thermal cycling profile included 3 cycles at 5±2°C to 50°C±2°C and 3 days of maturation at 5°C±2°C. Thus, samples were heated at 10°C / h until 50°C±2°C was reached, then cooled at 20°C / h (first cycle), 10°C / h (second cycle) and 5°C / h (third cycle) until 5°C±2°C was reached. Finally, the suspension was aged by stirring at 5°C±2°C for 3 days. [Figure 12]Figure 12 contains two tables: the top table shows the results of HPLC-CAD analysis of Foxy-5-L-histidine salt. The bottom table shows the results of HPLC-CAD analysis of the N-methyl-D-glucamine salt of Foxy-5. As can be seen, the ratios determined using the HPLC-CAD method were all close to the predicted ratios of 1:1, 1:2 and 1:3. The slight deviations observed are likely due to the hygroscopic nature of the samples. [Figure 13] FIG. 13 shows, from bottom to top, an overlay of the HT-XRPD patterns of Foxy-5-L-histidine (1:2) from Experiment ID GEN5, Experiment ID TCP7 (thermal cycled in acetone), and Experiment ID TCP9 (thermal cycled in acetonitrile / water (90 / 10)). [Figure 14] FIG. 14 shows, from bottom to top, an overlay of the HT-XRPD patterns of Experiment ID GEN8, Experiment ID TCP11 (thermal cycled in ethanol), and Experiment ID TCP15 (thermal cycled in ethyl acetate) Foxy-5-L-histidine (1:3). [Figure 15] FIG. 15 shows, from bottom to top, an overlay of the HT-XRPD patterns of Foxy-5-N-methyl-D-glucamine (MEG) (1:2) Experiment ID GEN7, Experiment ID TCP18 (thermal cycled in tetrahydrofuran), and Experiment ID TCP20 (thermal cycled in ethyl acetate). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] Detailed Description As mentioned in the Overview, a linear liquid phase manufacturing process for Foxy-5 hexapeptide (also referred to herein as Foxy-5) has been published in Applicant's international patent application WO 2020 / 120198 for a product concentration for final lyophilization of only 3 g / L due to the limited solubility of the salt-free drug substance (DS) in water. As further mentioned, initial strategies to overcome this problem resulted in the generation of the trisodium salt of Foxy-5, which has good aqueous solubility but was found to have extremely low stability rendering the trisodium salt unusable as a new drug substance candidate.

[0035] Foxy-5 has been found to form highly soluble compositions with a variety of nitrogenous bases, and surprisingly, many of these compositions are significantly more stable than the trisodium salt of Foxy-5, potentially allowing for a substantial increase in yield for commercial manufacture of Foxy-5.

[0036] This discovery was made while screening for salts of Foxy-5 using the following potential "salt formers": ammonium hydroxide, L-arginine, calcium hydroxide, choline hydroxide, diethylamine, L-lysine, L-histidine, magnesium hydroxide, N-methyl-D-glucamine and tromethamine. Given the known problems associated with the sodium salt of Foxy-5, this selection of salt formers was believed to provide a sufficient breadth of chemically distinct candidates that would ultimately also meet the regulatory requirements for pharmaceutical ingredients and excipients. Thus, the selected "salt formers" are selected from compounds with GRAS recognition and / or Stahl Class I or II designation (see PH Stahl and CG Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Second Edition, Wiley-VCH: Zuerich (2011)).

[0037] As previously described, the compositions obtained in the salt screening studies are hereafter referred to as "stoichiometrically isolated amorphous lyophilizates" for convenience, even though the compositions could not be adequately (stoichiometrically) characterized as salts. Mono-, di- and tri-salts of Foxy-5 It is also called.

[0038] The trisalt of Foxy-5 was prepared by adding approximately 3 equivalents of base to an aqueous suspension of 20–30 mg / mL of the free acid of Foxy-5 using two different approaches: adding the calculated amount of base all at once to an aqueous suspension of the free acid of Foxy-5, or adding the base slowly while maintaining the pH of the suspension below 6.0 during the addition.

[0039] Clear solutions were obtained for all but the calcium and magnesium salts which remained in suspension, indicating that solubilities of at least 20 g / L were obtained for all but the calcium and magnesium salts. The clear solutions were lyophilized and the solid lyophilizates were characterized by PXRD and HPLC (see the Examples section and Figure 10 for a summary of all compositions). All were found to be amorphous (see Figure 9 for illustrative PXRD diagrams). For some salt formers, successful attempts were made to produce tri-salts with solubilities of about 50 g / L, with some tri-salts exceeding 100 g / L.

[0040] The highly soluble trisodium salt previously investigated (see Background) was also prepared for comparison.

[0041] Di-salts were also prepared with all salt formers that gave clear solutions in the trivalent salt experiments, namely ammonium hydroxide, L-arginine, choline hydroxide, diethylamine, L-lysine, L-histidine, N-methyl-D-glucamine and tromethamine. Again, clear solutions were obtained in all cases, indicating that the di-salts of Foxy-5 also had aqueous solubilities of 20 mg / mL or greater. The solutions were lyophilized and the solid lyophilizates were characterized by PXRD and HPLC (see Examples section). All were found to be amorphous. For some salt formers, successful attempts were made to prepare di-salts with solubilities of about 50 g / L. Mono-salts were prepared in a similar manner.

[0042] The resulting lyophilizates were all amorphous solids as evidenced by PXRD analysis. In most cases the solids were slightly hygroscopic.

[0043] In a first aspect, the present invention provides a solid composition comprising For-Met-Asp-Gly-Cys-Glu-Leu-OH (sequence 1, Foxy-5) and a nitrogenous base, wherein the nitrogenous base is a compound selected from ammonia, quaternary ammonium hydroxides, alkylated guanidines, amino acids, and primary and secondary amines.

[0044] In an embodiment of the first aspect, the solid composition contains 0.5 to 3.1 equivalents of a nitrogen base selected from ammonia, quaternary ammonium hydroxides, alkylated guanidines, amino acids, and primary and secondary amines.

[0045] In a preferred embodiment of the first aspect, the present invention provides a "tri-salt" comprising Foxy-5 (For-Met-Asp-Gly-Cys-Glu-Leu-OH, sequence 1) and 2.5 to 3.1 equivalents of ammonia, a quaternary ammonium hydroxide, an alkylated guanidine, an amino acid, and a nitrogenous base selected from primary and secondary amines.

[0046] In another preferred embodiment of the first aspect, the present invention provides a "di-salt" comprising Foxy-5 (For-Met-Asp-Gly-Cys-Glu-Leu-OH, Sequence 1) and 1.50 to 2.49 equivalents of a nitrogenous base selected from ammonia, quaternary ammonium hydroxides, alkylated guanidines, amino acids, and primary and secondary amines.

[0047] In another embodiment of the first aspect, the invention provides a "mono salt" comprising Foxy-5 (For-Met-Asp-Gly-Cys-Glu-Leu-OH, Sequence 1) and 0.5 to 1.49 equivalents of a nitrogenous base selected from ammonia, quaternary ammonium hydroxides, alkylated guanidines, amino acids, and primary and secondary amines.

[0048] As noted in the Background section, the trisodium salt of Foxy-5 has high aqueous solubility but has surprisingly been found to be unstable compared to the free acid form. The main impurities in the sodium salt are: Cys disulfide of Foxy5 (dimer), Cys→Ala substitution of Foxy5, i.e., desulfurized derivative, and Asp Aspartimide Derivatives It was found that (see Figure 2).

[0049] Stability analysis of compositions according to the first aspect of the invention demonstrated that these compositions contain varying amounts of the same impurities as the known sodium salts. The change in said impurities over time also varies significantly between compositions.

[0050] Stability studies of compositions according to the first aspect (and already produced trisodium salts) at 40° C. for 2 and 4 weeks were carried out. Several general trends were found. As can be seen from FIG. 5, the absolute purity of the compositions when analyzed immediately after lyophilization (0 weeks) and when observed at 40° C. for 2 and 4 weeks was found to be substantially different. The purity of the tri-salt varied more than the purity of the di-salt (78-95% HPLC purity at 4 weeks for the tri-salt vs. 87-96% at 4 weeks for the di-salt). Furthermore, as can be seen from FIG. 6, the absolute purity of the compositions containing amino acids was generally higher after 4 weeks at 40° C. when compared to compositions containing other salt formers (4 week values: about 90% vs. about 85% for the tri-salt, about 95% vs. about 90% for the di-salt).

[0051] In one aspect, the present invention provides a composition comprising Foxy-5 and 2.5 to 3.1 equivalents of an amino acid, such as 2.8 to 3.05 equivalents of an amino acid, such as 2.9 to 3.02 equivalents of an amino acid, such as 2.95 to 3.01 equivalents of an amino acid, for example 3.0 equivalents of an amino acid.

[0052] In another aspect, the present invention provides a composition comprising Foxy-5 and 1.50 to 2.49 equivalents of an amino acid, such as 1.7 to 2.1 equivalents of an amino acid, for example 1.8 to 2.05 equivalents of an amino acid, such as 1.9 to 2.03 equivalents of an amino acid, for example 1.95 to 2.01 equivalents of an amino acid, for example 2.0 equivalents of an amino acid.

[0053] In a preferred embodiment, the present invention provides a composition comprising Foxy-5 and an amino acid selected from lysine, arginine, or histidine.

[0054] As already mentioned, many of the compositions of the present invention are hygroscopic to some extent, and many are found to become sticky when exposed to humid air.However, assay analysis combined with elemental analysis has revealed that some of the compositions of the present invention can be characterized as suitable salts that have formed hydrates, such as dihydrates and tetrahydrates, which are not sticky (see Examples).Since the compositions of the present invention are isolated as lyophilized amorphous solids (lyophilisates), such hydrates cannot be defined as precisely as crystalline hydrates, but nonetheless, many of the compositions have been found to be very clearly defined as salts with an approximate ratio of 1:2 ("di-salt") or 1:3 ("tri-salt") of Foxy-5 and salt-forming base.

[0055] Finally, Figure 7 shows a composition having a purity as measured by HPLC (area %) of at least 90% after 4 weeks storage at 40° C. As can be seen from the figure, the highly stable compositions of the invention are not limited to a particular salt form.

[0056] In another embodiment of the first aspect, therefore, the invention provides a composition, wherein the nitrogenous base is a compound selected from amino acids, ammonia, and primary and secondary amines.

[0057] In a preferred embodiment of the first aspect, the nitrogenous base used is selected from ammonia, L-lysine, L-histidine, N-methyl-D-glucamine and tromethamine.

[0058] In another preferred aspect, the present invention provides a composition comprising Foxy-5 and 1.50 to 2.49 equivalents, such as 1.7 to 2.1 equivalents, for example 1.9 to 2.03 equivalents, such as 1.95 to 2.01 equivalents, for example 2.0 equivalents of a nitrogenous base selected from ammonia, L-lysine, L-histidine and tromethamine.

[0059] In another preferred aspect, the present invention provides a composition comprising Foxy-5 and 2.5 to 3.1 equivalents, such as 2.9 to 3.03 equivalents, for example 2.95 to 3.01 equivalents, such as 3.0 equivalents, for example 2.5 to 3.1 equivalents of a nitrogenous base selected from L-histidine and N-methyl-D-glucamine.

[0060] In another preferred embodiment, the present invention provides compositions comprising the di-ammonium, di-histidine, tri-histidine, di-lysine, di-N-methyl-D-glucamine, tri-N-methyl-D-glucamine and di-tromethamine salts of Foxy-5, optionally containing from 0 to 5 equivalents of water relative to Foxy-5.

[0061] In particularly preferred aspects, the present invention provides compositions comprising Foxy-5 and 1.5 to 3.1 equivalents, such as 1.7 to 2.49 equivalents, such as 1.7 to 2.1 equivalents, or such as 2.5 to 3.1 equivalents of L-histidine, optionally comprising 0 to 5 equivalents of water relative to Foxy-5.

[0062] A second aspect of the present invention provides a method for producing a composition according to the first aspect, comprising the steps of: a) i. as a suspension in a solvent, or ii. As a powder The free acid form of For-Met-Asp-Gly-Cys-Glu-Leu-OH (sequence 1, Foxy-5) iii. mixing with 0.5 to 1.49 equivalents of a nitrogen base to produce a mono-salt of Foxy-5; iv. mixing with 1.50 to 2.49 equivalents of a nitrogenous base to produce a di-salt of Foxy-5; or v. mixing with 2.5 to 3.1 equivalents of a nitrogen base to produce a trisalt of Foxy-5; b) stirring the reaction mixture until a clear solution is obtained; and c) isolating the solid composition by precipitating, or freeze-drying or spray-drying the solution; The present invention provides a method for producing a composition, wherein the nitrogen base is a compound selected from ammonia, quaternary ammonium hydroxide, alkylated guanidine, amino acid, and primary and secondary amines, and all of steps a) to c) are carried out under an inert atmosphere as necessary.

[0063] In a preferred embodiment of the second aspect, the nitrogen base used for salt formation in step iii), iv) or v) is selected from ammonia, L-lysine, L-histidine, N-methyl-D-glucamine and tromethamine.

[0064] In a preferred embodiment, the concentration of Foxy-5 in step i) is about 20-30 mg / mL in water.In another preferred embodiment, the nitrogen base used for salt formation in step vi) is 1.50-2.49 equivalents, such as 1.7-2.1 equivalents, for example 1.9-2.03 equivalents, such as 1.95-2.01 equivalents, for example 2.0 equivalents of a nitrogen base selected from ammonia, L-lysine, L-histidine and tromethamine.

[0065] In another preferred embodiment, the nitrogenous base used for salt formation in step v) is 2.5 to 3.1 equivalents, such as 2.9 to 3.03 equivalents, for example 2.95 to 3.01 equivalents, for example 3.0 equivalents of a nitrogenous base selected from L-histidine and N-methyl-D-glucamine.

[0066] As previously described, two different approaches were used in the preparation of compositions according to the first aspect: either the calculated amount of base is added all at once to an aqueous suspension of the free acid of Foxy-5, or the base is added slowly while maintaining the pH of the reaction mixture below 6.0 during the addition.

[0067] HPLC analysis of the compositions immediately after lyophilization revealed that titrating "slowly" produced compositions containing lower levels of impurities than compositions produced using the "fast" approach, as can be seen in Figure 8. As can be seen, the impact is greatest for the ammonia "tri-salt," which drops in purity from approximately 98% to 95% (slow addition → fast addition). In comparison, the purity of the tromethamine and tri-N-methyl-glucamine "tri-salts" is only slightly lower when these salts are formed by fast addition. Without being bound by theory, the inventors believe that this phenomenon may be related to the pKa of the bases forming the salts: ammonium hydroxide is the strongest of the three bases, with a pKa of 9.3, while both tromethamine and N-methylglucamine have pKas of 8.0.

[0068] In an embodiment of the second aspect, the nitrogen base used in step b) for salt formation is added all at once to the aqueous suspension of the free acid of Foxy-5. In another embodiment of the second aspect, the nitrogen base used in step b) for salt formation is added gradually to the aqueous suspension of the free acid of Foxy-5, while maintaining the pH of the reaction mixture below 6 during the addition.

[0069] In yet other embodiments of the second aspect, the final clear solution of step b is lyophilized to obtain a solid composition of the invention. In other embodiments of the second aspect, a solid composition is obtained from the final clear solution in step b by precipitation, including crystallization. In some embodiments, precipitation or crystallization is achieved by addition of one or more anti-solvents, evaporation, cooling, or a combination thereof.

[0070] Several of the compositions of the invention were selected for scale-up. As part of this, the initially isolated amorphous product was subjected to a thermal cycling step in which a suspension of the amorphous product in an organic solvent was subjected to 1-3 cycles of alternating heating and cooling from 5°C ± 2°C to 50°C ± 2°C, followed by an aging step in which the suspension was stirred at 5°C ± 2°C for 1-3 days. Surprisingly, the thermally cycled material was found to be less fluffy, less static and easier to handle than the lyophilized material.

[0071] In a third aspect of the present invention, the solid composition obtained in step c) of the second aspect is further subjected to i. Providing a suspension of the freeze-dried or spray-dried product in a solvent or solvent mixture; ii. subjecting the suspension to a thermal cycling step comprising 1-3 cycles of 5°C±2°C to 50°C±2°C, followed by aging the suspension at 5°C±2°C for 1-3 days; iii. isolating the product after thermal cycling, for example by filtration or centrifugation; subjecting the mixture to a thermal cycling process including In the thermal cycling step, the suspension is heated at 10°C ± 2°C / hr until it reaches 50°C ± 2°C, and then the suspension is cooled at 5°C ± 2°C / hr until it reaches 5°C ± 2°C. a. 20°C ± 2°C / hour for the first cycle; b. 10°C ± 2°C / hr for the second cycle, and c. 5°C ± 2°C / hr for the third cycle Finally, the suspension is aged by stirring at 5° C.±2° C. for 1-3 days before isolation, e.g., by filtration or centrifugation.

[0072] The temperature profile of the thermal cycling process is illustrated in FIG.

[0073] In a preferred embodiment of the third aspect, the organic solvent is selected from ethanol, acetone, tetrahydrofuran (THF), acetonitrile / water (90 / 10) and ethyl acetate.

[0074] In preferred embodiments of the third aspect, the thermally cycled products are Foxy-5-L-histidine salts in ratios of 1:2 and 1:3, or Foxy-5-N-methyl-D-glucamine salts in a ratio of 1:2. Representative HT-XRPD traces can be seen in Figures 13-15. EXAMPLES

[0075] Determination of pKa of Foxy-5 The pKa of Foxy-5 free acid (Lot: 1058263) was measured by potentiometric titration at 25°C using a Sirius T3 with SiriusT3Control Vers. 2.0.0.0 software. An automated aqueous titration method was used with 1.0 mg of solid API dissolved in 1.5 mL of ISA water as the starting value, and three consecutive titrations were performed on the same sample. For all titrations, the starting pH of the sample solution was adjusted to 12 with 0.5 M KOH and slowly titrated to a final pH of 2 with 0.5 M HCl.

[0076] The titration curves were fitted using SiriusT3Refine Vers. 2.0.0.0 software, and the corresponding pKa values ​​were calculated. The pKa values ​​of all the theoretically predicted four acidic sites were measured in the experimentally accessible range, with an RMSD of 0.071. The fitting results are shown in Table 1.

[0077] Theoretical pKa values ​​were also calculated using ACD / Percepta 14.51.0 (build 3382) in classical and GALAS modes, and the ACD_Prediction Vers. 2.0.0.0 package in the Sirius T3 Vers. 2.0.0.0 software. The latter is the program used to measure pKa. The software assigned the calculated values ​​to specific sites on the molecule. As shown in Table 1, the three prediction methods gave values ​​that agreed with each other within 0.1 to 0.5 units. The experimental values ​​were quite close to the predicted values, with the measured values ​​for the thiol of the cysteine ​​group and the carboxylic acid of the L-aspartic acid being approximately in the middle of the corresponding predicted range, and the measured values ​​for the terminal carboxylic acid and the carboxylic acid of the L-glutamic acid group being slightly outside the upper limit of the predicted range.

[0078] [Table 1]

[0079] Below, compositions prepared in accordance with the present invention are described in detail, divided into "tri-salts", i.e., Foxy-5 compositions containing about 3 equivalents of a nitrogenous base, "di-salts", i.e., Foxy-5 compositions containing about 2 equivalents of a nitrogenous base, and "mono-salts", i.e., Foxy-5 compositions containing about 1 equivalent of a nitrogenous base.

[0080] Stability test data for all compositions formed and the starting material (Foxy-5 free acid) itself was measured at 0, 2 and 4 weeks of storage at 40° C. and is included in FIG.

[0081] Analytical conditions for stability measurement The following parameters of a substance-specific UPLC method were used for purity determination of stability samples:

[0082] [Table 2]

[0083] Determination of Foxy-5 salt ratio Elemental analysis (C, H, N, O, and S) was initially performed on several of the isolated Foxy-5 salts, namely the ammonia di- and tri-salts, and the histidine di- and tri-salts (see Examples below). For these salts, the measurements were only reasonably consistent with the various hydrates of the salt, so it was decided to explore other analytical methods to determine ratios in order to unambiguously prove that the methods disclosed herein produced 1:1, 1:2, and 1:3 salts of Foxy-5.

[0084] Therefore, the ratios of nine different Foxy-5 salts (1:1, 1:2 and 1:3 ratios of L-histidine, ammonium and N-methyl-D-glucamine) were determined by HPLC-CAD and 1 H-NMR was used to investigate this.

[0085] Solubility in water The solubility of the nine salts was determined using a quantitative solubility method. The material is suspended in water for 24 hours, after which an aliquot of the mother liquor is analyzed by UPLC. If the material has dissolved after 24 hours, the solubility is stated as greater than (>).

[0086] A summary of the solubility results is shown in Table 3.

[0087] [Table 3]

[0088] The 1:2 and 1:3 salts prepared all exhibited solubilities greater than 20 mg / ml, with the 1:1 salt exhibiting a solubility of approximately 20 mg / ml. In comparison, the solubility of the free Foxy-5 hexapeptide is approximately 3 mg / ml.

[0089] HPLC-CAD An HPLC-CAD method was developed for the determination of the ratio of Foxy-5-L-histidine salt and Foxy-5-N-methyl-D-glucamine salt, but this method is not suitable for the ammonium salt of Foxy-5 because the ammonium salt is included in the mobile phase.

[0090] Calibration curves were constructed for L-histidine and N-methyl-D-glucamine using a stock solution with a concentration of 0.1 mg / ml and ten injection volumes (1 μl to 5.5 μl in 0.5 μl increments). The amount of Foxy-5 salt used in the analysis was calculated so that the concentration of the counter ion was approximately 0.1 mg / ml. Ratios were then calculated using the predicted versus measured areas (see the top table in Figure 12 for L-histidine and the bottom table in Figure 12 for N-methyl-D-glucamine). All ratios determined by the HPLC-CAD method were close to the predicted ratios of 1:1, 1:2, and 1:3. Thus, HPLC-CAD is well suited to determine the ratios of Foxy-5 and its respective counter ions. This HPLC method cannot determine the ratios of the ammonium salts of Foxy-5, but this issue can be circumvented by appropriately modifying the HPLC mobile phase.

[0091] 1 H-NMR 1 H-NMR shows that the coformer is organic. 1 When H-NMR is available, it is the standard method to determine the ratio of API to its coformer in salt screening. L-histidine and N-methyl-D-glucamine are 1 It contains protons that can be measured by H-NMR. Ammonia contains protons, but it is usually 1 Quantification is not possible because H-NMR cannot be measured.

[0092] therefore, 1 An attempt was made to determine the ratios of Foxy-5 to L-histidine and Foxy-5 to N-methyl-D-glucamine by H-NMR. The methyl group of N-methyl-D-glucamine shifted from 2.26 ppm before salt formation to 2.48 ppm after salt formation, which allowed for a good determination of the 1:2 salt ratio of Foxy-5-N-methyl-D-glucamine. Integration of the methyl groups showed ratios of 1:2.15 for GEN16, 1:2.01 for TCP18, and 1:2.02 for TCP20. Thus, 1 H-NMR is an excellent method for determining the ratio of Foxy-5-L-NMG salts.

[0093] However, it was difficult to determine the ratio of Foxy-5-L-histidine salts. GEN14 was determined to have the expected ratio of 1:2, while the ratio of the other samples was determined to be about 1:0.1, which can be explained by the low solubility of L-histidine in DMSO-d6. L-histidine probably started to crystallize in the NMR solvent after some time and therefore was not detected during the measurements.

[0094] New samples were prepared in D2O and indeed the L-histidine protons showed a very strong signal, but the ratio of Foxy-5 to L-histidine was lower than expected, i.e. 1:1.4 for the 1:2 sample and 1:2.1 for the 1:3 sample. The integrals of the peptides themselves also deviated from the molecular structure. Therefore, it was decided to measure them with an NMR method named "qNMR" which has a longer relaxation delay. GEN15 and TCP11, Foxy-5-L-histidine salts with a ratio of 1:3, were tested. The qNMR method gave proton integrals in good agreement with the molecular formula of the peptides and the ratio with L-histidine was determined to be close to 1:3.

[0095] In conclusion, it can be said that the above analytical methods for determining the ratios demonstrate that 1:1, 1:2 and 1:3 salts of Foxy-5 with good water solubility can be produced by the methods disclosed herein. The solubility measurements show a clear trend from low solubility of the free Foxy-5 peptide (3 mg / ml), through increased solubility of the 1:1 salt (approximately 20 mg / ml), to significantly increased solubility of the 1:2 and 1:3 salts (up to 150 mg / ml).

[0096] Scale-up and thermal cycling of Foxy-5 salt Three salts were selected for scale-up: Foxy-5-Histidine in ratios of 1:2 and 1:3, and Foxy-5-N-Methyl-D-Glucamine in a ratio of 1:2. These salts were selected because they have solubilities greater than 31 mg / ml and can maintain a pH < 6 during production. The 1:2 salt of ammonium hydroxide also meets these requirements, but there is currently no accurate analytical method available for determining this salt ratio, so it was not selected for scale-up at this time.

[0097] All selected salts were scaled up to the 300 mg scale, and solids were obtained in all cases (Foxy-5-L-histidine (1:2), Foxy-5-L-histidine (1:3) and Foxy-5-N-methyl-D-glucamine (1:2)). 1 The solids were analyzed using H-NMR, UPLC-MS, HPLC-CAD and TGMS.

[0098] The resulting solid was subjected to a temperature profile in five solvents (see Figure 11). The results of the thermal cycling experiments are shown in Table 4.

[0099] [Table 4]

[0100] XRPD patterns of the thermally cycled samples are shown in Figures 13-15. Scale-up and thermal cycling resulted in mostly amorphous material, although some samples were found to be deliquescent both before and after thermal cycling. For the HIS 1:3 salt, the XRPD pattern contained several peaks indicative of crystallization. On closer inspection, the peaks were found to be due to a slight excess of pure L-histidine that precipitated as monoclinic crystals.

[0101] Surprisingly, the thermal cycled material was found to be easier to handle than the freeze-dried material, as it was less fluffy and less prone to static electricity.

[0102] Formation of "tri-salt" The trisalt of Foxy-5 is generally prepared by adding a base to a suspension of Foxy-5 in water or other suitable solvent. The base can be added all at once or gradually, neat or in solution, while maintaining the pH below 6 during the preparation.

[0103] Arginine Trisalt Experiment ARG-P1 89.7 mg (0.129 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a glassy white suspension; 67.7 mg (3 equiv.) of L-arginine was added under N2 purge to give a clear colorless solution with pH 7.31; Stirred at room temperature for 2 hours to give a clear colorless solution with pH 7.27; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 18 hours 15 minutes to give a white solid; Characterized by PXRD; Stored in freezer and characterized twice by HPLC after 14 days. PXRD confirmed the sample was amorphous; HPLC has purities of 96.47 area % and 96.40 area % for two injections.

[0104] Calcium Trisalt Experiment Ca-P1 89.6 mg (0.129 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity > 18.2 MΩ cm) to give a glassy white suspension; 28.8 mg (3 equiv.) of Ca(OH)2 was added to give a thin white suspension with a pH of 12.36; Stirred at room temperature for 2 hours to give a thin white suspension with a pH of 12.34; Stirred at room temperature overnight to give a white suspension; The experiment was terminated due to failure to reach minimum solubility.

[0105] Choline Trisalt Experiment CHO-P1 89.6 mg (0.129 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a white suspension; 95.4 μL (3 equiv) of 46% choline hydroxide (aq) (density = 1.073 g / L) was added under N2 to give a beige solution with pH 8.51; Stirred at room temperature for 2 hours to give a beige solution with pH 8.43; Filtered through a PVDF 0.2 μm syringe filter into a 10 mL round bottom flask; The solution was frozen and lyophilized to give a beige solid; Characterized by PXRD; Characterized twice by HPLC. PXRD confirmed the sample was amorphous; HPLC has purities of 92.14 area % and 92.08 area % for two injections.

[0106] Diethylamine trisalt Experiment DEA-P1 90.5 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩ cm) to give a glassy white suspension; 40.2 μL (3 equiv.) of diethylamine (density = 0.707 g / L) was added under N2 purging to give a clear colorless solution with pH 5.43; Stirred at room temperature for 2 h to give a clear colorless solution with pH 5.45; Syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 18 hours 15 minutes to give a white solid; Characterized by PXRD; Stored in the freezer and characterized twice by HPLC after 14 days; Portions of this sample were stored in a closed container at 40° C. for 2 and 4 weeks and tested by HPLC; Observed to have a glassy appearance at 40° C. for 2 and 4 weeks. PXRD confirmed the sample to be amorphous; HPLC gives two injections with purities of 97.26 area % and 97.22 area %.

[0107] Lysine Trisalt Experiment LYS-P1 90.3 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a glassy white suspension; 56.8 mg (3 equiv.) of L-lysine was added under N2 purge to give a clear colorless solution with pH 6.39; Stirred at room temperature for 2 h to give a clear colorless solution with pH 6.46; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 18 h 15 min to give a white solid; Characterized by PXRD; Stored in freezer and characterized by HPLC after 14 days; Portions of this sample were stored in a closed container at 40°C for 2 and 4 weeks and characterized by HPLC twice. PXRD confirmed the sample to be amorphous; HPLC gave purities of 97.44 area % and 97.39 area % for two injections.

[0108] Magnesium Trisalt Experiment Mg-P1 89.6 mg (0.129 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩ cm) to give a glassy white suspension; 22.7 mg (3 equiv.) of Mg(OH)2 was added to give a thick white suspension (pH was not measurable due to thickness); Stirred at room temperature for 2 hours to give a white suspension with pH 9.06; Stirred at room temperature overnight to give a white suspension; Experiment terminated as minimal solubility was not reached. No salt with solubility > 30 g / L was obtained and therefore not characterized.

[0109] Sodium Trisalt Experiment Na-P1 90.5 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩ cm) to give a glassy white suspension; 388.6 μL (3 equiv.) of 1 M NaOH (aq) was added under N2 purge to give a clear colorless solution with pH 8.23;Stirred at room temperature for 2 hours to give a clear colorless solution with pH 8.17;Filtered through a syringe filter (13 mm diameter, PVDF 0.45 μm) into a 10 mL round bottom flask;Frozen the resulting solution in dry ice;Lyophilized for 24 hours 05 minutes to give a white solid;Stored in freezer and characterized by HPLC after 5 days;Sample was difficult to weigh due to being extremely hygroscopic;Parts of this sample were stored in a closed container at 40°C for 2 weeks and 4 weeks and tested twice by HPLC;The 4 week sample was difficult to weigh due to being hygroscopic. PXRD confirmed the sample was amorphous;Trace amounts of NaCl may be present;HPLC has a purity of 95.11 area % for two injections.

[0110] Ammonia Trisalt Experiment NH3-P8 100.3 mg (0.144 mmol) of Foxy-5 hexapeptide was weighed into a 15 mL Supelco vial; 3.333 mL of ultrapure water was added under N2 purge (resistivity ≥ 18.2 MΩ cm) to give a glassy suspension. The suspension was stirred at 500 rpm and a pH electrode was inserted. 0.1 M NH4OH (aq) was dosed at 0.05 mL / min with periodic pauses to measure pH. At 15 min, 0.50 mL of base was added, pH was 3.84; at 45 min, 1.34 mL total of base was added, pH was 4.09; at 1 hr 06 min, 2.37 mL total of base was added, pH was 4.42; at 1 hr 14 min, 2.74 mL total of base was added, pH was 4.64; a clear, colorless solution was obtained; at 1 hr 45 min, 3.74 mL total of base was added (equivalent to 2.59 equiv.), pH was 5.81; dosing was stopped; at 3 hr 40 min, pH was 6.00; the remaining 0.58 mL of base was not added; the experiment was terminated. The clear, colorless solution was placed in a 20 mL round bottom flask, frozen in a mixture of dry ice and isopropanol, and lyophilized. HPLC (2 runs) and elemental analysis were performed. By HPLC, the purity of the two injections is 98.08 and 98.05 area %, with corresponding assays of 68.76% and 68.71%, respectively. The ratio of nitrogen to sulfur content is not perfectly matched in the trisalt, but this is not surprising since the amount added (based on gravimetric calculations) was only 2.59 equivalents. The elemental analysis of the product (C, H, N, O, and S) (table below) is in good agreement with a salt containing 2.6 equivalents of ammonia and 2 equivalents of water.

[0111] [Table 5]

[0112] N-Methyl-D-glucamine trisalt Experiment NMG-P5 90.3 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 7 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩ cm). A pH meter was inserted and the pH was confirmed to be 2.66. N2 purging was applied and stirring was performed at 700 rpm. 0.78 mL of a 0.5 M aqueous solution of N-methyl-D-glucamine (4.8803 g in 50 mL water) was added slowly using a dosimeter and the pH was measured at multiple time points. After adding 0.25 mL of 0.5 M NMG (aq), a cloudy solution was observed with some material present at the bottom of the reaction vessel. The pH was 4.01. After adding 0.70 mL of the 0.5 M N-methyl-D-glucamine solution, a clear solution was obtained; the pH was 5.51. A total of 0.74 mL of 0.5 M N-methyl-D-glucamine solution was added (equivalent to 2.85 equiv); pH was 5.99. After stirring for 2 hours, the pH of the solution was 6.01. The clear, colorless solution was placed in a 20 mL round bottom flask and frozen in dry ice; lyophilized overnight. A white solid was obtained and characterized by PXRD and HPLC. PXRD confirmed the sample was amorphous; HPLC showed purities of 96.90 area % and 96.69 area % for two injections.

[0113] Tromethamine trisalt Experiment TRO-P3 90.0 mg (0.1295 mmol) of Foxy-5 hexapeptide was weighed into a 7 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩ cm). A pH meter was inserted and the pH was confirmed to be 2.69. N2 purging was applied and stirring was performed at 700 rpm. A suspension was observed. 0.39 mL of a 0.5 M aqueous solution of tromethamine (1.2115 g in 20 mL water) was added slowly over 30 min using a dosimeter and the pH was measured at multiple time points. After the addition of 0.29 mL (1.12 equiv.) of 0.5 M TRO (aq.), nearly all solids had dissolved and the pH was 4.04. After the addition of 0.59 mL of 0.5 M TRO solution (2.28 equiv.), a clear solution was obtained; the pH was 4.99. A total of 0.71 mL of 0.5 M TRO solution was added (equivalent to 2.74 equiv); pH was 5.95. After stirring for 2 hours, the pH of the solution was 5.97. The clear colorless solution was placed in a 20 mL round bottom flask; frozen in the freezer; lyophilized overnight. A white solid was obtained and characterized by PXRD. The sample was then stored in the freezer and characterized twice by HPLC after 5 days. By HPLC, the purity of the two injections is 98.34 area % and 98.35 area %.

[0114] Histidine trisalt Experiment HIS-P2 100.4 mg (0.145 mmol) of Foxy-5 hexapeptide was weighed into a 7 mL Supelco vial; 3.33 mL of ultrapure water was added under N2 purge (resistivity ≥ 18.2 MΩ cm) and a suspension of white gel-like solid was observed; Stirred at 500 rpm and an electrode was inserted to confirm pH was 2.64; 0.0985 M L-histidine (aq) was dosed at 0.1 mL / min with a pause to measure pH; 0.30 mL of base was added in 2 min, pH was 3.50; 1.00 mL total of base was added in 9 min, pH was 3.50; 2.00 mL total of base was added in 19 min. The pH was 4.23;An almost clear solution with some gelatinous solid clumps was observed;3.00 mL total added in 29 min, pH 4.61;4.00 mL total added in 39 min, pH 5.11;A clear colorless solution was observed;4.38 mL total added in 43 min, pH 5.29;Stirred for several hours;3 hours 23 minutes after dosing started, pH was measured at 5.27 and experiment was terminated;The clear colorless solution was poured into a 20 mL round bottom flask and the resulting solution was frozen in dry ice and lyophilized for 19 hours 05 minutes to give a fluffy white solid;HPLC (2 runs) and elemental analysis were performed. PXRD confirmed the sample was amorphous (Figure 8). HPLC gave purities of 98.25 area % and 98.21 area % for the two injections with corresponding assays of 62.12% and 61.95%, respectively. The elemental analysis of the product (C, H, N, O and S) (table below) is in good agreement with an amorphous product that is the trisalt tetrahydrate.

[0115] [Table 6]

[0116] Determination of the solubility of histidine trisalt 12.9 mg of the above histidine salt was carefully redissolved in water at a stirring speed of 500 rpm and a water input rate of 0.01 mL / min. Complete dissolution was observed after the addition of a total of 0.08 mL of water, corresponding to a solubility of at least 161 g / L.

[0117] Experiment HIS-GEN8 70.1 mg (0.101 mmol) of Foxy-5 hexapeptide was slurried in 5 ml water at room temperature and 0.1 M histidine (aq) was added slowly with stirring until approximately 2.97-2.98 molar equivalents were reached. The pH was 5.45. The experiment was terminated and the colorless solution was lyophilized as described above. HT-XRPD confirmed the sample was amorphous; UPLC showed a purity of 96.0 area %.

[0118] HPLC-CAD confirmed the sample to be a 1:3 Foxy-5 hexapeptide:L-histidine salt.

[0119] Experiment HIS-GEN15 Experiment HIS-P2 was scaled up as follows: 199.7 mg of Foxy-5 hexapeptide was combined with 134.2 mg of L-histidine in 7 ml of degassed water and stirred until the starting material was completely dissolved. The pH was 5.41. The solution was then lyophilized overnight. A white solid was obtained, with a ratio of Foxy-5 to L-histidine of 1:3.19 by HPLC-CAD, accurately determined by qNMR in D2O to be 1:3 (Foxy-5:L-histidine). Chemical purity is 98.9 area % by UPLC analysis.

[0120] Five samples (approximately 50 mg each) of the solid from experiment HIS-GEN15 were suspended in 1000 μL ethanol (experiment TCP11), 1000 μL acetone (experiment TCP12), 1000 μL THF (experiment TCP13), 200 μL acetonitrile / water (90:10) (experiment TCP14) and 2000 μL ethyl acetate (experiment TCP15). Thermal cycling was performed and aging was allowed to take place for 3 days at approximately 5° C. (see temperature profile in FIG. 11). After the aging period, the solid was recovered by centrifugation and the wet and vacuum dried samples were analyzed by HT-XRPD. The material from the thermal cycling experiments was amorphous, however that from ethyl acetate was found to have improved material handling properties, especially compared to the lyophilized material. The lyophilized Foxy-5 showed By itself However, even compositions with nitrogen bases have a significant tendency to become electrostatically charged and are often fine, bulky materials which are therefore difficult to handle (eg during weighing).

[0121] The formation of "Zisho" The di-salts of Foxy-5 are generally prepared by adding a base to a suspension of Foxy-5 in water or other suitable solvent. The base can be added all at once or gradually, neat or in solution, while maintaining the pH below 6 during the preparation.

[0122] Arginine di-salt Experiment ARG-P2 90.5 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a glassy white suspension; 45.1 mg (2 equiv.) of L-arginine was added under N2 purge to give a clear colorless solution with pH 4.57; Stirred at room temperature for 2 hours to give a clear colorless solution with pH 4.55; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 19 hours 30 minutes to give a white solid; Characterized by PXRD; Stored in freezer and characterized twice by HPLC after 6 days. PXRD confirmed the sample was amorphous; HPLC has purities of 97.70 area % and 97.67 area % for two injections.

[0123] Choline salt Experiment CHO-P2 89.1 mg (0.128 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity > 18.2 MΩcm) to give a glassy white suspension; 63.6 μL (2 equiv.) of 46% choline hydroxide (aq) (density = 1.073 g / L) was added under N2 purge to give a beige solution with pH 4.78; Stirred at room temperature for 2 h to give a beige solution with pH 4.78; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 19 h 30 min to give a white solid; Characterized by PXRD; Characterized twice by HPLC. PXRD confirmed the sample to be amorphous; HPLC gave purities of 94.42 area % and 94.27 area % for two injections.

[0124] Diethylamine di-salt Experiment DEA-P2 90.1 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a glassy white suspension; 26.8 μL (2 equiv.) of diethylamine (density = 0.707 g / L) was added under N2 purge to give a thin white suspension with pH 4.68; Stirred at room temperature for 2 h to give a clear colorless solution with pH 4.54; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 19 h 30 min to give a white solid; Characterized by PXRD; Stored in freezer and characterized by HPLC after 6 days; Portions of this sample were stored in a closed container at 40 °C for 2 and 4 weeks and tested by HPLC in duplicate. PXRD confirmed the sample to be amorphous; HPLC gave purities of 97.30 area % and 97.41 area % for two injections.

[0125] Lysine di-salt Experiment LYS-P2 89.6 mg (0.129 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a glassy white suspension; 37.0 mg (2 equiv.) of L-lysine was added under N2 purge to give a clear colorless solution with pH 4.53; Stirred at room temperature for 2 hours to give a clear colorless solution with pH 4.52; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 19 hours 30 minutes to give a white solid; Characterized by PXRD; Stored in freezer and characterized by HPLC after 6 days; Portions of this sample were stored in a closed container at 40°C for 2 weeks and 4 weeks and tested by HPLC in duplicate. PXRD confirmed the sample to be amorphous; HPLC gave purities of 97.69 area % and 97.73 area % for two injections.

[0126] Ammonia Di-salt Experiment NH3-P6 100.7 mg (0.145 mmol) of Foxy-5 hexapeptide was weighed into a 7 mL Supelco vial; 3.33 mL of ultrapure water was added under N2 purge (resistivity ≥ 18.2 MΩ cm) and a gel-like white suspension was observed; Stirred at 500 rpm and an electrode was inserted to confirm the pH was 2.63; 1 M NH4OH (aq) was dosed at 0.05 mL / min with a pause to measure the pH; 0.10 mL of base was added in 2 min and the pH was 3.19; A total of 0.20 mL of base was added in 4 min and the pH was 3.11; a colorless solution was observed on top of the white suspension; at 5 min, 0.29 mL of base (di-salt stoichiometry) was added and the pH was 3.18; at 7 min, the pH was 5.49 and the solution was nearly clear; at 12 min, the pH was 4.60 and the solution was clear; at 2 h 12 min, the pH was measured to be 4.56 and the experiment was terminated; the clear colorless solution was placed in a 20 mL round bottom flask and the resulting solution was frozen in dry ice and stored in a freezer for 5 days; it was then lyophilized for 27 h 35 min to give a white solid; HPLC (2 runs) and elemental analysis were performed. PXRD confirmed the sample was amorphous. By HPLC, the purity of the two injections was 97.62 area % and 97.66 area %, with corresponding assay values ​​of 89.32% and 89.08%, respectively. The elemental analysis of the product (C, H, N, O and S) (table below) is in good agreement with an amorphous product that is the di-salt dihydrate.

[0127] [Table 7]

[0128] Experiment NH3-GEN6 81.3 mg (0.117 mmol) of Foxy-5 hexapeptide was slurried in 5 mL of water at room temperature and 0.1 M histidine (aq) was added slowly with stirring until approximately 1.97-1.98 molar equivalents were reached. The pH was 4.36. The experiment was terminated and the colorless solution was lyophilized as described above. HT-XRPD confirmed the sample was amorphous; UPLC showed a purity of 93.7 area %.

[0129] Due to the presence of ammonia in the HPLC mobile phase, it was not possible to confirm that the isolated compound was the 1:2 Foxy-5 hexapeptide:NH3 salt.

[0130] N-Methyl-D-glucamine di-salt Experiment NMG-P6 90.2 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 7 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩ cm). A pH meter was inserted and the pH was confirmed to be 2.67. The headspace was purged with N2 (N2 atmosphere) and stirred at 700 rpm. A suspension was observed. 0.52 mL of a 0.5 M aqueous solution of N-methyl-D-glucamine (4.8803 g in 50 mL water) was added slowly using a dosimeter and the pH was measured at multiple time points. After adding 0.35 mL of 0.5 M NMG (aq), nearly all of the solids had dissolved and a somewhat lumpy solution was observed. The pH was 4.13. After adding 0.50 mL of the 0.5 M N-methyl-D-glucamine solution, a clear solution was obtained; the pH was 4.57. A total of 0.52 mL of 0.5 M N-methyl-D-glucamine solution was added (corresponding to 2.0 equiv); the pH was 4.64. After stirring for 2 hours, the pH of the solution was 4.63. The clear, colorless solution was placed in a 20 mL round bottom flask; the resulting solution was frozen in dry ice and lyophilized overnight. A white solid was obtained and characterized by PXRD and HPLC. Portions of this sample were stored in a closed container at 40° C. for 2 and 4 weeks and tested twice by HPLC; after 2 weeks of storage at 40° C., it was observed to have a sticky, glassy appearance. PXRD confirmed the sample was amorphous; HPLC showed purities of 96.64 area % and 96.58 area % for two injections.

[0131] Experiment NMG-GEN7 79.3 mg (0.114 mmol) of Foxy-5 hexapeptide was slurried in 5 mL of water at room temperature and 0.5 M N-methyl-D-glucamine solution (aqueous) was added slowly with stirring until approximately 1.97-1.98 molar equivalents were reached. The pH was 4.73. The experiment was terminated and the colorless solution was lyophilized as described above. HT-XRPD confirmed the sample was amorphous; UPLC showed a purity of 95.0 area %.

[0132] HPLC-CAD confirmed the sample to be a 1:2 Foxy-5 hexapeptide:N-methyl-D-glucamine salt.

[0133] Experiment NMG-GEN16 Experiment NMG-P6 was scaled up as follows: 200.3 mg of Foxy-5 hexapeptide was combined with 113.5 mg of N-methyl-D-glucamine in 7 ml of degassed water and stirred until the starting material was completely dissolved. The pH was 4.68. The solution was then lyophilized overnight. A white solid was obtained and analyzed by UPLC, TGMS, 1 It was characterized by H-NMR and HPLC-CAD, and the chemical purity was 99.0% (area %) by UPLC.

[0134] NMG-GEN16 1 H-NMR measurement and HPLC-CAD confirmed that the sample was a 1:2 Foxy-5 hexapeptide:N-methyl-D-glucamine salt.

[0135] The resulting solid was subjected to thermal cycling as follows.

[0136] Five samples (approximately 50 mg each) of the solid from experiment NMG-GEN16 were suspended in 1000 μL ethanol (experiment TCP16), 1000 μL acetone (experiment TCP17), 1000 μL THF (experiment TCP18), 200 μL acetonitrile / water (90:10) (experiment TCP19) and 2000 μL ethyl acetate (experiment TCP20). Thermal cycling was performed and aging was allowed to take place at approximately 5° C. for 3 days (see temperature profile in FIG. 11). After the aging period, the solid was recovered by centrifugation and the wet and vacuum dried samples were analyzed by HT-XRPD. The material from the thermal cycling experiment was amorphous, however that from ethyl acetate was found to have improved material handling properties, especially compared to the lyophilized material. The lyophilized Foxy-5 showed By itself However, even compositions with nitrogen bases have a significant tendency to become electrostatically charged and are often fine, bulky materials which are therefore difficult to handle (eg during weighing).

[0137] Tromethamine di-salt Experiment TRO-P2 90.1 mg (0.130 mmol) of Foxy-5 hexapeptide was weighed into a 4 mL Supelco vial; 3 mL of degassed ultrapure water was added (resistivity ≥ 18.2 MΩcm) to give a glassy white suspension; 31.4 mg (2 equiv.) of tromethamine was added under N2 purge to give a clear colorless solution with pH 4.88; Stirred at room temperature for 2 hours to give a clear colorless solution with pH 4.86; Filtered through a syringe filter (13 mm diameter, PVDF 0.2 μm) into a 10 mL round bottom flask; The resulting solution was frozen in dry ice; Lyophilized for 19 hours 30 minutes to give a white solid; Characterized by PXRD; Stored in freezer and characterized twice by HPLC after 6 days. PXRD confirmed the sample was amorphous; HPLC has purities of 97.77 area % and 97.78 area % for two injections.

[0138] Histidine disalt Experiment HIS-P3 99.2 mg (0.143 mmol) of Foxy-5 hexapeptide was weighed into a 7 mL Supelco vial; 3.33 mL (i.e., 30 mg / mL) of ultrapure water was added under N2 purge (resistivity ≥ 18.2 MΩ cm) and a suspension of white gel-like solid was observed; Stirred at 500 rpm and an electrode was inserted to confirm a pH of 2.65; 0.0985 M L-histidine (aq) was dosed at 0.1 mL / min with pauses to measure pH; 0.17 mL of base was added in 1 min, pH was 3.10; 1.00 mL total of base was added in 10 min, pH was 3.90; 2.00 mL total of base was added in 20 min. , pH was 4.40;An almost clear solution with some clumps of gelatinous solid was observed;A total of 2.82 mL was added at 28 minutes, pH was 4.73;At 1 hour 10 minutes, a clear colorless solution was observed;2 hours 28 minutes after the start of dosing, pH was measured at 4.50 and the experiment was terminated;The clear colorless solution was added to a 20 mL round bottom flask and the resulting solution was frozen in dry ice and lyophilized for 19 hours 05 minutes to give a fluffy white solid;HPLC and elemental analysis were performed;A portion of this sample was stored in a sealed container at 40°C for 2 weeks and 4 weeks and tested by HPLC;The sample was observed to remain a fluffy white solid after storage at 40°C for 2 weeks and 4 weeks. By HPLC, the purity of the two injections was 98.02 area % and 98.00 area %, with corresponding assay values ​​of 67.88% and 67.86%, respectively. Elemental analysis of the product (C, H, N, O and S, table below) is in good agreement with an amorphous product that is the di-salt dihydrate.

[0139] [Table 8]

[0140] Determination of the solubility of histidine di-salts The above experiment was repeated using half the amount of water (60 mg / ml) for the initial slurry of Foxy-5 hexapeptide, resulting in a final concentration of 31.6 g / L of histidine disalt at a pH of 5.82. The experiment was repeated again adding the histidine solution to the neat (solid) Foxy-5 hexapeptide to give a final concentration of 49.3 g / L at a pH of 5.78. In both cases the final solution was frozen and lyophilized for 25 hours to give a fluffy white solid.

[0141] Experiment HIS-GEN5 78.4 mg (0.113 mmol) of Foxy-5 hexapeptide was slurried in 5 mL of water at room temperature and 0.1 M histidine (aq) was added slowly with stirring until approximately 1.97-1.98 molar equivalents were reached. The pH was 4.61. The experiment was terminated and the colorless solution was lyophilized as described above. HT-XRPD confirmed the sample was amorphous; UPLC showed a purity of 93.9 area %.

[0142] HPLC-CAD confirmed the sample to be 1:2 Foxy-5 hexapeptide:L-histidine salt.

[0143] Experiment HIS-GEN14 Experiment HIS-P3 was scaled up as follows: 220.1 mg of Foxy-5 hexapeptide was combined with 98.5 mg of L-histidine in 7 ml of degassed water and stirred until the starting material was completely dissolved. The pH was 4.65. The solution was then lyophilized overnight. A white solid was obtained, and HPLC-CAD showed a ratio of Foxy-5 to L-histidine of 1:2.10, whereas 1 The ratio was accurately determined to be 1:2.03 by H NMR, and the chemical purity is 98.9 area % by UPLC analysis.

[0144] Five samples (approximately 50 mg each) of the solid material from experiment HIS-GEN14 were suspended in 1000 μL ethanol (experiment TCP6), 1000 μL acetone (experiment TCP7), 1000 μL THF (experiment TCP8), 200 μL acetonitrile / water (90:10) (experiment TCP9) and 2000 μL ethyl acetate (experiment TCP10). Thermal cycling was performed and aging was allowed to proceed for 3 days at approximately 5° C. (see temperature profile in FIG. 11). After the aging period, the solid material was recovered by centrifugation and wet and vacuum dried samples were analyzed by HT-XRPD. The material from the thermal cycling experiments was amorphous, but that from ethyl acetate was found to have improved material handling properties, especially compared to the lyophilized material. The lyophilized Foxy-5 showed By itself However, even compositions with nitrogen bases have a significant tendency to become electrostatically charged and are often fine, bulky materials which are therefore difficult to handle (eg during weighing).

[0145] Formation of "mono-salt" The mono-salt of Foxy-5 is generally prepared by adding a base to a suspension of Foxy-5 in water or other suitable solvent. The base can be added all at once or gradually, neat or in solution, while maintaining the pH below 6 during the preparation. The reaction mixture is then stirred until the starting materials are dissolved. The final solution of the mono-salt is optionally filtered and then freeze-dried or spray-dried.

[0146] Histidine monosalt Experiment HIS-GEN2 90.6 mg (0.131 mmol) of Foxy-5 hexapeptide was slurried in 5 ml water at room temperature and 0.1 M histidine (aq) was added slowly with stirring until approximately 0.97-0.98 molar equivalents were reached. The pH was 3.88. The experiment was terminated and the slightly milky, colorless solution was lyophilized as described above. HT-XRPD confirmed the sample was amorphous; UPLC showed a purity of 95.2 area %.

[0147] HPLC-CAD confirmed the sample to be 1:1 Foxy-5 hexapeptide:L-histidine salt.

[0148] Ammonia Monosalt Experiment NH3-GEN3 92.6 mg (0.134 mmol) of Foxy-5 hexapeptide was slurried in 5 mL water at room temperature and 1 M NH4OH (aq) was dosed at 0.05 mL / min with stirring until approximately 0.99 molar equivalents were reached. The pH was 3.87. The experiment was terminated and the slightly milky, colorless solution was lyophilized as described above. HT-XRPD confirmed the sample was amorphous; UPLC shows a purity of 94.4 area %.

[0149] Due to the presence of ammonia in the HPLC mobile phase, it was not possible to confirm that the isolated compound was the 1:1 Foxy-5 hexapeptide:NH3 salt.

[0150] N-Methyl-D-glucamine monosalt Experiment NMG-GEN4 89.5 mg (0.129 mmol) of Foxy-5 hexapeptide was slurried in 5 mL of water at room temperature and 0.26 mL (1 molar equivalent) of a 0.5 M aqueous solution of N-methyl-D-glucamine (4.88 g in 50 mL of water) was added slowly with stirring. After approximately 2 hours, a nearly clear, slightly opalescent solution was obtained. The pH was now 3.91. The experiment was terminated and the solution was lyophilized as described above. HT-XRPD confirmed the sample to be amorphous; UPLC gives a purity of 94.3 area %.

[0151] HPLC-CAD confirmed the sample to be 1:1 Foxy-5 hexapeptide:NMG salt.

Claims

1. 1. A solid composition comprising For-Met-Asp-Gly-Cys-Glu-Leu-OH (Sequence 1, Foxy-5) and a nitrogenous base, wherein the nitrogenous base is a compound selected from ammonia, quaternary ammonium hydroxides, alkylated guanidines, amino acids, and primary and secondary amines, and wherein the solid composition optionally comprises water.

2. 2. The solid composition of claim 1, comprising 0.5 to 3.1 molar equivalents of said nitrogen base relative to Foxy-5.

3. 3. The solid composition according to claim 1, wherein the nitrogen base is a compound selected from amino acids, ammonia, and primary and secondary amines.

4. 4. The solid composition according to claim 1, wherein the nitrogen base is selected from ammonia, L-lysine, L-histidine, N-methyl-D-glucamine and tromethamine.

5. 5. A solid composition according to any one of claims 1 to 4 comprising Foxy-5 and 1.50 to 2.49 equivalents, such as 1.7 to 2.1 equivalents, for example 1.9 to 2.03 equivalents, such as 1.95 to 2.01 equivalents, for example 2.0 equivalents of a nitrogenous base selected from ammonia, L-lysine, L-histidine and tromethamine.

6. 5. A solid composition according to any one of claims 1 to 4 comprising Foxy-5 and 2.5 to 3.1 equivalents, such as 2.9 to 3.03 equivalents, such as 2.95 to 3.01 equivalents, such as 3.0 equivalents of a nitrogenous base selected from L-histidine and N-methyl-D-glucamine.

7. 2. The solid composition of claim 1, wherein the salt is selected from di-ammonium salts, di-L-histidine salts, tri-L-histidine salts, di-L-lysine salts, di-N-methyl-D-glucamine salts, tri-N-methyl-D-glucamine salts, and di-tromethamine salts of Foxy-5, said salts being amorphous and optionally containing 0 to 5 equivalents of water relative to Foxy-5.

8. 3. The solid composition of claim 2, wherein the nitrogenous base is L-histidine.

9. 9. A solid composition according to claim 8, comprising Foxy-5 and 1.50 to 2.49 equivalents, for example 1.7 to 2.1 equivalents, of L-histidine.

10. 9. The solid composition of claim 8, comprising Foxy-5 and 2.5 to 3.1 equivalents of L-histidine.

11. A method for producing the solid composition according to any one of claims 1 to 10, comprising the steps of: a) i. as a suspension in a solvent, or ii. As a powder For-Met-Asp-Gly-Cys-Glu-Leu-OH (Sequence 1, Foxy-5) in its free acid form iii. mixing with 0.5 to 1.49 equivalents of a nitrogenous base to produce a mono-salt of Foxy-5; iv. mixing with 1.50 to 2.49 equivalents of a nitrogenous base to produce a di-salt of Foxy-5; or v. mixing with 2.5 to 3.1 equivalents of a nitrogenous base to produce a tri-salt of Foxy-5; b) stirring the reaction mixture until a clear solution is obtained; and c) isolating the solid composition by precipitating, crystallizing, or freeze-drying or spray-drying the solution; The method for producing a solid composition, wherein the nitrogen base is a compound selected from ammonia, quaternary ammonium hydroxide, alkylated guanidine, amino acid, and primary and secondary amines, and all steps a) to c) are carried out under an inert atmosphere as necessary.

12. The method for producing a solid composition according to claim 11, wherein water is used as a solvent.

13. A method for preparing a solid composition according to any one of claims 11 to 12, wherein the nitrogen base is added gradually to Foxy-5 while maintaining the pH of the reaction mixture below 6.

0.

14. A method for preparing a solid composition according to any one of claims 11 to 13, wherein the clear solution obtained in step b) is freeze-dried.

15. The obtained solid composition is further i. providing a suspension of the freeze-dried or spray-dried product in a solvent or solvent mixture; ii. subjecting the suspension to a thermal cycling step comprising 1-3 cycles of 5°C±2°C to 50°C±2°C, followed by aging the suspension at 5°C±2°C for 1-3 days; iii. Isolating the product after thermal cycling, for example by filtration or centrifugation; subjecting the mixture to a thermal cycling process including In the thermal cycling step, the suspension is heated at 10° C.±2° C. / hour until it reaches 50° C.±2° C., and then the suspension is cooled at 5° C.±2° C. / hour until it reaches 5° C.±2° C. a. 20°C ± 2°C / hr for the first cycle; b. 10° C.±2° C. / hr for the second cycle, and c. 5°C ± 2°C / hr for the third cycle and thereafter aging the suspension by stirring at 5°C±2°C for 1-3 days before isolation.

16. 16. The method for producing a solid composition according to claim 15, wherein the organic solvent is selected from ethanol, acetone, tetrahydrofuran (THF), acetonitrile / water (90 / 10) and ethyl acetate.